M&A Deal Summary

Piramal Enterprises Acquires RxElite

On January 28, 2009, Piramal Enterprises acquired life science company RxElite for 4M USD

Acquisition Highlights
  • This is Piramal Enterprises’ 2nd transaction in the Life Science sector.
  • This is Piramal Enterprises’ 6th largest (disclosed) transaction.
  • This is Piramal Enterprises’ 1st transaction in the United States.
  • This is Piramal Enterprises’ 1st transaction in Idaho.

M&A Deal Summary
Date 2009-01-28
Target RxElite
Sector Life Science
Buyer(s) Piramal Enterprises
Deal Type Add-on Acquisition
Deal Value 4M USD

Target

RxElite

Meridian,, Idaho, United States
RxElite, Inc. is a specialty pharmaceutical company that develops and markets generic prescription drug products in specialty generic markets. RxElite also operates an Israeli subsidiary that manufactures and markets complex active pharmaceutical ingredients and provides research and development services to pharmaceutical companies throughout the world.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Piramal Enterprises

Mumbai, India
Category Company
Founded 1947
Sector Healthcare Services
Employees3,000
Revenue 81.1B INR (2024)
DESCRIPTION

Piramal Enterprises is a diversified Indian conglomerate. Piramal Group operates healthcare, drug discovery and research, glass, real estate and financial services. Piramal Enterprises was founded in 1947 and is based in Mumbai, India.

DEAL STATS #
Overall 2 of 12
Sector (Life Science) 2 of 6
Type (Add-on Acquisition) 1 of 6
State (Idaho) 1 of 1
Country (United States) 1 of 5
Year (2009) 1 of 2
Size (of disclosed) 6 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2008-07-02 PlasmaSelect AG Haemaccel Brand

Germany

PlasmaSelect AG, Haemaccel Brand, Blood plasma expansion products are life-saving infusion pharmaceuticals that help maintain blood plasma volume until blood transfusion can be administered to the patient, in the event of blood loss. These products also serve a range of other critical care needs in hospitals and critical care facilities.

Buy €8M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2009-02-28 Minrad International

Orchard Park, New York, United States

Manufacturer of generic inhalation anesthetics.

Buy -
Mergr

Product

Company

Legal